Beate Wieseler

Summary

Country: Germany

Publications

  1. ncbi request reprint [Results registries for clinical trials--a milestone on the way to transparency in clinical research?]
    Beate Wieseler
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Koln
    Z Evid Fortbild Qual Gesundhwes 104:298-305. 2010
  2. pmc Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
    Dirk Eyding
    German Cancer Society, Berlin, Germany
    BMJ 341:c4737. 2010
  3. pmc Access to regulatory data from the European Medicines Agency: the times they are a-changing
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Im Mediapark 8 KölnTurm, Cologne, 50670, Germany
    Syst Rev 1:50. 2012
  4. doi request reprint Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Dillenburger Strasse 27, 51105 Cologne, Germany
    BMJ 344:d8141. 2012
  5. pmc Impact of inclusion of industry trial results registries as an information source for systematic reviews
    Regine Potthast
    Institute for Quality and Efficiency in Health Care, Cologne, Germany
    PLoS ONE 9:e92067. 2014
  6. pmc Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Cologne, Germany
    PLoS Med 10:e1001526. 2013
  7. pmc Reporting bias in medical research - a narrative review
    Natalie McGauran
    Institute for Quality and Efficiency in Health Care, Dillenburger Str 27, 51105 Cologne, Germany
    Trials 11:37. 2010
  8. pmc Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
    Michael Kohler
    Institute for Quality and Efficiency in Health Care, Im Mediapark 8, 50670 Cologne, Germany
    BMJ 350:h796. 2015
  9. doi request reprint [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences]
    Tatjana Kvitkina
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Koln, Deutschland Electronic address
    Z Evid Fortbild Qual Gesundhwes 108:528-38. 2014

Collaborators

  • Natalie McGauran
  • Thomas Kaiser
  • Julia Kreis
  • Michael Kohler
  • Tatjana Kvitkina
  • Regine Potthast
  • Ulrich Grouven
  • Michaela F Kerekes
  • Dirk Eyding
  • Kerstin Staeck
  • Katharina Biester
  • Ulrike Seay
  • Heike Kolsch
  • Anne Catharina Brockhaus
  • Gregor Moritz
  • Helmut Horn
  • Susanne Haag
  • Volker Vervölgyi
  • Anette Ten Haaf
  • Stefanie Reken
  • Monika Lelgemann
  • Martin Härter
  • Martin Gerken
  • Mandy Kromp

Detail Information

Publications9

  1. ncbi request reprint [Results registries for clinical trials--a milestone on the way to transparency in clinical research?]
    Beate Wieseler
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Koln
    Z Evid Fortbild Qual Gesundhwes 104:298-305. 2010
    ..The present paper describes the status quo of results registries, discusses registration requirements, and outlines the need to develop methods for the handling of results registries...
  2. pmc Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
    Dirk Eyding
    German Cancer Society, Berlin, Germany
    BMJ 341:c4737. 2010
    ..To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine...
  3. pmc Access to regulatory data from the European Medicines Agency: the times they are a-changing
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Im Mediapark 8 KölnTurm, Cologne, 50670, Germany
    Syst Rev 1:50. 2012
    ..In conclusion, regulatory data are an indispensable source for systematic reviews. Because of EMA's policy change, a milestone for data transparency in clinical research is within reach; let's hope it is not unnecessarily delayed...
  4. doi request reprint Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Dillenburger Strasse 27, 51105 Cologne, Germany
    BMJ 344:d8141. 2012
    ..To investigate to what extent three types of documents for reporting clinical trials provide sufficient information for trial evaluation...
  5. pmc Impact of inclusion of industry trial results registries as an information source for systematic reviews
    Regine Potthast
    Institute for Quality and Efficiency in Health Care, Cologne, Germany
    PLoS ONE 9:e92067. 2014
    ..Clinical trial results registries may contain relevant unpublished information. Our main aim was to investigate the potential impact of the inclusion of reports from industry results registries on systematic reviews (SRs)...
  6. pmc Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data
    Beate Wieseler
    Institute for Quality and Efficiency in Health Care, Cologne, Germany
    PLoS Med 10:e1001526. 2013
    ....
  7. pmc Reporting bias in medical research - a narrative review
    Natalie McGauran
    Institute for Quality and Efficiency in Health Care, Dillenburger Str 27, 51105 Cologne, Germany
    Trials 11:37. 2010
    ..This will allow for an independent review of research data, help fulfil ethical obligations towards patients, and ensure a basis for fully-informed decision making in the health care system...
  8. pmc Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
    Michael Kohler
    Institute for Quality and Efficiency in Health Care, Im Mediapark 8, 50670 Cologne, Germany
    BMJ 350:h796. 2015
    ....
  9. doi request reprint [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences]
    Tatjana Kvitkina
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Koln, Deutschland Electronic address
    Z Evid Fortbild Qual Gesundhwes 108:528-38. 2014
    ..By increasingly considering patient-relevant outcomes in approval studies, pharmaceutical companies can create the necessary data basis for the early benefit assessment. ..